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Background: Patients with stable COPD show improvements in exercise capacity and muscular function after the
application of whole body vibration. We aimed to evaluate whether this modality added to conventional physiotherapy
in exacerbated hospitalised COPD patients would be safe and would improve exercise capacity and quality of life.
Methods: 49 hospitalised exacerbated COPD patients were randomized (1:1) to undergo physiotherapy alone or
physiotherapy with the addition of whole body vibration. The primary endpoint was the between-group difference
of the 6-minute walking test (day of discharge – day of admission). Secondary assessments included chair rising
test, quality of life, and serum marker analysis.
Results: Whole body vibration did not cause procedure-related adverse events. Compared to physiotherapy alone,
it led to significantly stronger improvements in 6-minute walking test (95.55 ± 76.29 m vs. 6.13 ± 81.65 m; p = 0.007) and
St. Georges Respiratory Questionnaire (−6.43 ± 14.25 vs. 5.59 ± 19.15, p = 0.049). Whole body vibration increased
the expression of the transcription factor peroxisome proliferator receptor gamma coactivator-1-α and serum levels
of irisin, while it decreased serum interleukin-8.
Conclusion: Whole body vibration during hospitalised exacerbations did not cause procedure-related adverse
events and induced clinically significant benefits regarding exercise capacity and health-related quality of life that
were associated with increased serum levels of irisin, a marker of muscle activity.
Trial registration: German Clinical Trials Register DRKS00005979. Registered 17 March 2014.
Keywords: Exercise, COPD exacerbation, Cytokine biology, Pulmonary rehabilitationBackground
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive lung disease characterized by irreversible ob-
struction of the airways. The progression of the disease
is associated with recurrent exacerbations that may lead
to decline in lung function, quality of life and exercise
capacity while increasing the risk for mortality [1]. Cach-
exia and muscle atrophy [2] are critical extra-pulmonary
manifestations of COPD. It is well established that
skeletal muscle function (strength and endurance) and* Correspondence: koczulla@med.uni-marburg.de
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unless otherwise stated.structure (fiber quality, capillary density and metabolic
capacity) are altered in patients with COPD i.e. shifted
towards a decreased oxidative capacity of the muscle [3].
In addition, it was shown that the anabolic-catabolic ra-
tio is shifted towards the catabolic state of the muscle,
which is accompanied by ischemia-related apoptosis in-
jury [4].
Pulmonary rehabilitation improves exercise perform-
ance, dyspnea, and quality of life, reduces the effects of
acute exacerbations and prolongs the interval between
exacerbations [5,6]. Current guidelines recommend pul-
monary rehabilitation for all stages of COPD but do not
explicitly recommend it during an acute exacerbation
[1]. The central components of rehabilitation are exer-
cise and strength training. It is hypothesized that thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics
Measured parameter Control WBV p-value
Gender [M/F] 12/8 14/6 0.74
Age [years] 70.4 ± 10.1 66.4 ± 9.93 0.24
Height [cm] 170.3 ± 10.63 168.9 ± 9.28 0.5
Weight [kg] 75.15 ± 19.73 79.5 ± 23.48 0.7
BMI [kg/m2] 25.75 ± 6.42 27.88 ± 7.87 0.51
FEV1 [% pred.] 38.4 ± 17.82 32.71 ± 13.18 0.43
GOLD stages [I/II/III/IV) 1/4/7/7 0/1/11/8 0.3
Current Smokers [%] 26.23 30 1.00
Mean Packyears* 47,50 ± 35,94 39,64 ± 27,91 0.53
On ICS before study [%] 64.29 70.59 1.00
On OCS before study [%] 14.29 23.53 0.66
Antibiotics [yes/no] 8/12 11/9 0.53
Data are displayed as mean ± standard deviation. There were no statistical
differences between both groups. Mann–Whitney-U test was used to compare
ordinal variables, categorial variables (gender, GOLD stages and antibiotics)
were tested using the Exact Fisher test. BMI: Body mass index; FEV1: Forced
exspiratory volume in one second; ICS: inhaled corticosteroids; OCS:
Oral corticosteroids.
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proliferator-activated receptor-γ coactivator 1α (PGC1-α)
[7-12] is relevant for the reconstitution of body strength by
exercise training. PGC1-α stimulates expression of FNDC5,
a membrane protein that is cleaved and secreted as a newly
identified hormone called Irisin [13]. The upregulation of
PGC1-α has been shown to decrease inflammation and in-
crease angiogenesis [14].
Whole body vibration (WBV) is a novel exercise train-
ing modality performed on a vibrating platform that
moves in sinusoidal oscillations, during which static and
dynamic exercises can be performed [6]. A randomized
clinical trial has demonstrated greater improvements in
a number of exercise tests in the group of COPD pa-
tients (GOLD stages III and IV) trained on the WBV
platform compared to a group that was conventionally
trained [6].
In the past decades research described pathological
features of COPD patients which included lung tissue
remodeling, fibrosis, pulmonary and systemic inflamma-
tion, lung vascular remodeling, and angiogenesis [15,16].
For that reason, we also evaluated putative beneficial effect
of standard physiotherapy programme complemented with
WBV relative to standard physiotherapy programme by
measuring serum markers of angiogenesis (ICAM-1, VEGF
and ACE) and apoptosis (gelsolin, soluble Fas Ligand/
TNFSF6, soluble Fas (CD95)/TNFRSF6).
We conducted a proof of concept study in the form of
a randomized clinical trial, in which we added WBV
training to conventional physiotherapy in a group of pa-
tients hospitalised for a COPD exacerbation and com-
pared this group to COPD subjects that only underwent
conventional physiotherapy. The goal was to evaluate
if WBV training is safe and improves exercise capacity
and quality of life, and whether putative improvement
is associated with measurable changes in circulating
levels of irisin, a recently described hormonal marker
of muscle activity.
Methods
Patients and study design
COPD patients hospitalized due to severe COPD exacerba-
tions at our hospital between November 2010 and July
2012 were asked for their interest and informed voluntary
consent to participate in our clinical trials. Pneumonia was
ruled out by chest x-ray. All included patients were treated
with an intensification of inhaled bronchodilators and a
short term course of systemic corticosteroids. Further infor-
mation regarding baseline characteristics can be found in
Table 1. This hypothesis generating trial has the ethical
approval of the local ethics committee (University of
Marburg, AZ 197/10).
Within the first 24 hours of hospitalization, 49 COPD
patients were randomised to participate in one of twoprogrammes. The randomization was performed by a
third party (a statistician from the sleep laboratory of the
University of Marburg). A computer generated list was
used to produce envelopes that were stored in a locked
room. The investigator who wanted to include a patient
called the statistician, reported the patient’s identifica-
tion number and received the allocation to one of both
treatment groups.
Group 1 was a standard physiotherapy programme
(Control group, n = 20: 5 min mobilisation, 5 min pas-
sive movement, and 10 min respiratory exercises), group
2 was the standard programme complemented with ses-
sions on the WBV device (WBV group, n = 20; Galileo™,
Novotec Medical, Pforzheim, Germany). Physiotherapy
consisted of mobilisation to bedside and stand, respira-
tory therapy and passive muscle movements. In the
WBV group additional training was performed in a
supervised manner 3×2 min/day on the vibrating
platform. The patient stood with bended knees on the
platform according to published recommendations
[17]. The side-alternating movements of the device
cause muscle contractions on the entire flexor and
extensor chain of muscles in the legs and the trunk [6].
Both training programmes started at the day of study
inclusion (the same day or the day after the patient`s
admission to the hospital). Details on the training
procedures can be found in the Additional file 1: Table S1.
The physiotherapists that performed bed-side standard
physiotherapy and researchers that performed assess-
ments were blinded for treatment allocation of the
patient.
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On the days of study inclusion and at the day of
discharge from the hospital we performed lung func-
tion tests according to ATS/ERS standard procedures
[18], ultrasound measurement of rectus femoris cross-
sectional area (M. rect. fem.) [19], 6-minute walking
test (6-MWT) [20], chair rising test (CRT) (time
needed for sitting down and standing up 5 times) as
described before [6,17], Saint Georges Quality of Life
Questionnaire (SGRQ) [21], COPD assessment test
(CAT) [22]. Assessors were blinded for the allocation
of the patients.Laboratory analysis
Serum level of C-reactive protein (CRP), white blood
cells (WBC), alpha-1-antitrypsin (AAT), and interleukin-8
(IL-8) were determined at the routine clinical chemistry
laboratory directly at hospitalisation and inclusion (base-
line) and on the day of discharge. For the quantitative de-
termination of serum irisin concentrations a commercial
ELISA kit (Aviscera Bioscience, INC) was used. Serum
samples were measured as duplicate in a plate reader fol-
lowing the instructions manual (Tecan infinite® F200pro).
The standard range was between 0,082-1280 ng/ml with a
sensitivity of 0,1-0,2 ng/ml.
For quantification of serum ICAM-1/CD54, ACE and
VEGF DuoSet ELISA Development kits (R&D Systems®)
were used. Each serum sample was measured as dupli-
cate and the ELISAs were implemented as recom-
mended in the instruction manual. The standard ranges
were between 125–8000 pg/ml for ACE and 15.625-
2000 pg/ml for ICAM-1/CD54 and VEGF.
The relative quantification of the transcription factor
PCG1-α in serum was performed using Western Blot
analyses. Each serum sample was separated by 10%
SDS-Polyacrylamid-gelelectrophoresis, transferred to
PVDF membrane and detected with a primary antibody
against PCG1-α (polyclonal IgG antibody coupled to
HRP (Antibodies-online, GmbH) produced in goat,
dilution 1:500 in TBST (is mixture of Tris-Buffered
Saline and Tween 20) supplemented with 5% milk
powder, incubation over night at 4°C). Detection of
enhanced chemiluminescence was performed after treat-
ment with secondary antibody (Anti-goat IgG, peroxidase
conjugated (Sigma Aldrich®) dilution 1:20000 in TBST
with 3% milk powder, 1h at room temperature) with
intas SCIENCE IMAGING ChemoCam system. After
development (10 min) relative quantification of indi-
vidual band volumes was performed using LabImage
1D, 1D Gel and Western Blot Analysis Software (BIO-
TEC FISCHER) with normalization to one reference
sera per blot (for representative sample see Additional
file 2: Figure S1).Statistical analysis
In this proof-of-concept study the main outcome meas-
ure was the between-group difference of the 6-minute
walking test (day of discharge – day of admission). Data
are expressed as mean ± standard deviation unless stated
otherwise. For comparing values at admission and dis-
charge within a group, the Wilcoxon matched-pairs
signed-ranks test was employed. To determine between
group differences a delta was calculated in each group,
in which the difference between the input measurements
and final measurement was computed. For these deltas,
the Mann–Whitney U-test was conducted to test for
differences between the groups. Correlation analysis was
performed using Spearman’s correlation coefficient. SPSS
20 (IBM GmbH, Ehningen, Germany) and GraphPad 5.0
(GraphPad Software, Inc., La Jolla, USA) were used. A p-
value of < 0.05 was defined as significant. Due to missing
data on WBV in exacerbated COPD patients no formal
power calculation could be performed.
Results
Patient demographics
Between November 2010 to July 2012, 57 patients were
screened, 49 were randomized and 40 patients com-
pleted the trial (Figure 1). Dropouts were replaced until
20 patients in each group finished the trial. No differen-
tial dropout was noted (3/23 vs. 6/26; p = 0.49; Fisher’s
exact test). At baseline, there were no significant differ-
ences in patient characteristics between the groups. No
significant difference in the length of stay could be de-
tected (p = 0.58) (Table 1). A single patient with COPD
GOLD 1 was included in the Control group. We analysed
it carefully. This patient suffered from comorbidities and
had severe symptoms and might display a cluster type
which has been described by other groups before (severe
symptoms, preserved lung function) [23].
Lung function
During the time interval between hospital admission and
discharge, FEV1 increased significantly in both groups
(CON: 37.9 ± 17.41% pred. to 43.23 ± 22.8% pred., p = 0.03;
WBV: 32.71 ± 13.18% pred. to 36.71 ± 13.89% pred., p =
0.04). Comparing the deltas between both groups no sig-
nificant difference was detected (p = n.s.).
Exercise capacity
As illustrated in Figure 2A, the 6MWT increased signifi-
cantly in WBV, but not in the control group (WBV: from
167.9 ± 117.46 m to 263.45 ± 124.13 m; p < 0.001 and
CON: from 203.79 ± 126.11 m to 198.67 ± 101.37 m, p =
n.s.). The difference between the delta of both groups
was significant (CON 6.13 ± 81.65 m vs. WBV 95.55 ±
76.29 m; p = 0.007; Figure 2A).
Figure 1 Trial Profile. 57 hospitalised patients were screened for randomisation. 3 were not eligible due to pneumonia, 5 patients declined to
participate. In the Control (CON) group, 6 patients discontinued training (early discharge: 3; withdrew consent: 2; death: 1). In the whole body
vibration (WBV) group, 3 patients discontinued the study (early discharge: 1; withdrew consent: 2).
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Test (CRT). The time needed for the CRT did not
change significantly in CON group (from 18.52 ± 7.32
sec to 28.51 ± 32.05 sec; p = 0.14) but significantly
decreased in WBV group (from 19.19 ± 7.43 sec to
17.02 ± 7.04 sec; p = 0.02; Figure 2B). Again, there wasFigure 2 Exercise capacity and functional testing. 6-MWT (A) and Chair
walking test (6-MWT; n = 19) and decreased the time needed for the chair
comparing admission and discharge in the control group (n = 14, n = 14), u
deltas between both groups we found significantly greater effects in the Wa significant difference between the groups comparing
the deltas (CON 4.04 ± 9.18 vs. WBV −2.17 ± 8.31; p =
0.003; Figure 2B). There was a negative correlation be-
tween the Delta 6MWT and the Delta CRT (r = −0.48;
p = 0.04), indicating consistency between both exercise
capacity tests.-Rising-Test (B). Whole body vibration (WBV) increased the 6-minute
rising test (CRT; n = 14); no significant differences could be detected
sing Wilcoxon matched-pairs signed-ranks test. When comparing the
BV group. * p < 0.05; ** p < 0.005; *** p < 0.001.
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As shown in Figure 3, conventional physiotherapy did
not change SGRQ (67.61 ± 15.22 to 69.66 ± 18.0) and
CAT (24,26 ± 9.14 to 22,65 ± 7.24). In the WBV group,
a significant improvement was found regarding CAT
(29,05 ± 6.45 to 25,1 ± 5.65; p = 0.02), while SGRQ did
not reach statistical significance (74,22 ± 13.84 to 67,79 ±
18.52, p = n.s.). Comparing the deltas between CON and
WBV, a significant difference was found only regarding
SGRQ (p = 0.049; Figure 3A). Evaluation of the specific do-
mains of the SGRQ, revealed significant group differences
only for the activity domain (p = 0.005; Additional file 3:
Figure S2). Although the decrease in CAT was more pro-
nounced in the WBV group, the difference between groups
was statistically not significant (p = 0.1; Figure 3B). The
deltas of SGQR and CAT correlated significantly with each
other (r = 0.53; p < 0.001).PGC1-α and irisin
Serum PGC1-α levels did not change in the CON
group (428.17 ± 249.99 ng/ml to 398.22 ± 272.05 ng/
ml, p = n.s.) but significantly increased in the WBV
group (460.02 ± 262.28 ng/ml to 529.26 + 260.76 ng/
ml; p < 0.001; Figure 4A). Comparing the deltas be-
tween both groups, a significant difference was found
(CON −29.95 ± 204.08 ng/ml vs. WBV 69.24 ± 75.9 ng/
ml; p = 0.02).
Similarly as for PGC1-α, serum levels of irisin did not
change significantly in the CON group (934.54 ± 581.98 ng/
ml to 791.98 ± 273.83 ng/ml, p = n.s.) but increased in the
WBV group (785.96 ± 423.93 ng/ml to 1195.85 ± 875.7 ng/
ml; p = 0.01; Figure 4B). Comparing the deltas (discharge –
admission) there was a significant difference in favour of
the WBV group (CON 142.56 ± 596.26 ng/ml vs. WBV
409.89 ± 610.61 ng/ml; p = 0.009).Figure 3 Quality of Life. SGRQ (A) and CAT (B). Whole body vibration (W
(SGRQ; n = 20) and COPD Assessment Test (CAT; n = 20); conventional physio
(Wilcoxon matched-pairs signed-ranks test). When comparing the deltas betwee
favour of WBV in the SGRQ, but not in the CAT score. * p < 0.05.Markers of inflammation
On admission to the hospital, both groups had elevated
levels of acute phase proteins (CRP, AAT), chemokine
(IL-8) and white blood cell counts. The increased levels
of WBC counts between the period of admission to dis-
charge in both groups was most likely due to the effects
of systemic steroids, which had been given to all pa-
tients. CRP, AAT, and IL-8 decreased from admission to
discharge (Additional file 4: Figure S3). Comparing the
deltas between both groups, the decrease of IL-8 was
more pronounced in WBV (Additional file 4: Figure S3;
p = 0.04). No other significant inter-group differences
could be detected (Additional file 5: Table S2).
Markers of apoptosis, angiogenesis and remodelling
In both study groups serum markers of angiogenesis
(Intercellular adhesion molecule-1 (ICAM-1), vascular
endothelial derived growth factor (VEGF), and angio-
tensin converting enzyme (ACE)) and apoptosis (gelso-
lin, soluble Fas Ligand/TNFSF6, soluble Fas (CD95)/
TNFRSF6) showed changes towards increased vascu-
larisation and decreased apoptosis. However, we found
no significant differences regarding these markers be-
tween the two groups (Additional file 5: Table S2).
Adverse events and length of hospital stay
No adverse events were noted that were related to
Whole Body Vibration (WBV). There was no difference
in the length of hospital stay (CON: 8.63 ± 6.16 days;
WBV: 8.58 ± 3.81 days; p = 0.58)
Discussion
To our knowledge this is the first randomized trial asses-
sing WBV in patients that had been hospitalized because
of a COPD exacerbation. We found that WBV improved
exercise capacity and quality of life. In addition, thereBV) had a positive impact on St. Georges Respiratory Questionnaire
therapy did not influence significantly on SGRQ (n = 19) or CAT (n = 19)
n both groups (Mann–Whitney-U test) we found a significant difference in
Figure 4 Markers of muscle activity. PGC1-α (A) and irisin (B). Whole body vibration (WBV) increased peroxisome-proliferator-activated
receptor-γ coactivator 1α (PGC1-α) transcription (relative band volume in Western blot analysis; n = 17 for both groups) and serum irisin levels in
WBV only. When comparing the deltas between both groups (Mann–Whitney-U test) we found a significant difference in favour of WBV regarding
the expression of PGC1-alpha and the expression irisin. * p < 0.05; ** p < 0.005; *** p < 0.001.
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muscle activity markers that may be induced by the
exercise.
A growing body of literature has reported benefit of
WBV for patients with cystic fibrosis, [24] multiple scler-
osis [25] and stroke [26]. To date, trials regarding effi-
cacy of WBV in patients with COPD are scarce. Results
from two studies investigating the effects of WBV therapy
in patients with stable COPD showed a significantly greater
improvement in the 6MWT, and a significant decrease in
maximum oxygen desaturation during the 6-MWT than
compared to patients in control group [6,27].
There is a major medical need to improve treatment
of patients hospitalized for COPD exacerbations. So far
these patients are treated primarily with drugs – bron-
chodilators, steroids and antibiotics. Recently, studies
have been published that evaluate muscle training con-
cepts during exacerbations. Troosters et al. evaluated re-
sistance training and demonstrated improvement of the
6MWD by a median of 34 m after patient discharge
[28]. In a small pilot study (n = 15), Abdeallaoui et al.
tested neuromuscular electrostimulation and concluded
that neuromuscular stimulation is effective in counteracting
muscle dysfunction and decreasing oxidative stress [29]. So
far, there are no published data analyzing the effects of
WBV in patients with COPD exacerbations. With this as a
background, we aimed to quantify the clinical benefit of
WBV therapy in a group of patients hospitalised for a
COPD exacerbation.
We were able to demonstrate that the addition of WBV
therapy to a physiotherapy regimen enhances exercise cap-
acity and quality of life. Specifically, we observed a strong
effect on 6MWD, which increased by 95.55 ± 76.29 m. The
magnitude of the 6WMD improvement was comparable to
that described by Pleguezuelos et al. (81.2 m) in the stable
phase of the disease [27].Interestingly, 19/20 patients in WBV group (compared
to 9/19 in the control group) improved 6MWD by more
than 35 m, which is considered as a minimal clinical im-
portant difference (MCID) [30]. Furthermore, 16 out of
20 WBV patients (compared to 12 out of 19 in the
control group) displayed improvements in SGRQ of 4 or
more units. So far, only one study investigated the bene-
ficial effects of WBV on quality of life in COPD patients
and found no difference between WBV and control
groups [6]. We guess that the differences between our
and previous results could be attributed to the nature
of vibration, intensity, and time or amplitude of vibra-
tion performance. Due to the paucity of data only
preliminary recommendation exist on the practical ap-
proach to WBV [17].
When comparing WBV to standard physiotherapy alone
(Control) we had to notice that standard physiotherapy
only led to very minor improvements. It is well known
that the peripheral muscle strength decreases during
an hospitalization of COPD [31] Furthermore, a very
recent overview states that convincing evidence for the
effectiveness of physiotherapy during a hospitalized ex-
acerbation of COPD is missing [32] and the recent
BTS guidelines on COPD and pulmonary rehabilitation
do not cover that topic [33]. The marginal improve-
ments raise the question on what ground patients were
discharged. However, regarding QoL and discharge it
has to be acknowledged (Additional file 3: Figure S2)
that also patients in the control group improved the
symptom subdomain of the SGRQ but did not show an
overall improvement. As the decision to discharge a
patient is mainly depended on symptoms it seems
reasonable why patients had been discharged despite
having a worse overall QoL score.
The mechanism of vibration stimulus is not wholly
understood; however, it is hypothesized that vibration
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creases osteogenesis [34]. It is suggested that some of
the best-recognized effects of exercise on muscle are
mediated by the transcriptional coactivator PGC1-α [14].
PGC1-α is induced in muscle by exercise and stimulates
mitochondrial biogenesis, angiogenesis and provides re-
sistance to muscular dystrophy [14]. The benefits of ele-
vated muscle expression of PGC1-α are believed to go
beyond the muscle tissue itself. For example, transgenic
mice with mildly elevated muscle PGC1-α are resistant
to diabetes and have a prolonged life-span [35]. PGC1-α
stimulates expression and secretion of hormone irisin,
which causes an increase in total body energy expenditure
and resistance to obesity-linked insulin-resistance [36].
Hence, irisin reflects benefits of exercise and muscle
activity.
We found that clinical improvements in the WBV
group paralleled with a marked increase in serum levels
of PGC1-α and irisin, the systemic markers linked to
muscle physiology. It is important to point out that al-
though the net exercise time was short; we still were
able to observe changes in circulating levels of PGC1-α/
irisin. To the best of our knowledge, this is the first time
that the suggested connection between physical exercise
training and the PGC1-α/irisin pathway is supported by
the findings from a randomized clinical trial.
When compared to controls, the WBV group also
showed a pronounced decrease of serum levels of IL-8
whereas levels of angiogenesis markers, such as ICAM-
1, VEGF, and ACE, and apoptosis markers, such as gel-
solin, soluble Fas Ligand/TNFSF6, soluble Fas (CD95)/
TNFRSF6), did not differ. We cannot say whether the
effect of WBV on the IL-8 levels results from a direct
modulation of chemokine production by vibration, or
if this modulation is secondary to an improvement in
muscular properties. Better muscular activity could
lower inflammation and result in decreased production of
proinflammatory cytokines/chemokines, a possibility that,
however, has not yet been properly investigated.
Notably, WBV therapy was well tolerated by the exac-
erbated COPD patients and no adverse effects were
noted during the training program. It was discussed that
exercise training during acute exacerbation of COPD
may accelerate systemic inflammation [28]. Despite these
worries, no increase in serum levels of acute phase pro-
teins, such as CRP and AAT, was found in the WBV
training group relative to controls.
This randomized clinical trial has some limitations.
First, it was a single centre study, and only 49 patients
were randomized. Due to the severity of the disease, es-
pecially for the first time point (inclusion), some patients
were not able to perform the 6-MWD. To eliminate a
potential bias, we calculated the intra-individual effect
by setting the admission value to 3 m, which was thelowest values that was obtained by the study. This maxi-
mises the effect in the control group. Nevertheless, the
inter-group difference in the 6MWD increase was still
significant in a favour of WBV (p = 0.009) (Additional
file 6: Figure S4). Although the assessment of the SGRQ
and CAT did not yield identical results, the deltas of
SGQR and CAT correlated significantly with each other
(r = 0.53; p < 0.001), demonstrating good agreement. We
did not perform a sham procedure; therefore the pa-
tients were not blinded for the allocation. Finally, muscle
biopsies before and after WBV therapy would provide a
major insight in the muscle metabolism, vascularisation
and inflammation.
We conclude that WBV is safe, feasible and may ex-
hibit positive effects on clinical parameters (exercise
capacity, quality of life) in COPD patients hospitalized
due to an exacerbation of their underlying disease. Since
the addition of WBV to common exercise training in-
creases the physical activity and enhances circulating
levels of the hormone irisin in exacerbated subjects with
COPD, it is possible that this training modality within a
short timeperiod improves muscle activity, attenuates
inflammatory pathways, and improves quality of life. Larger
studies are needed to define optimal intensity and duration
of WBV as well as to investigate its possible long-term
effects.
Conclusion
Whole body vibration exercise in hospitalised COPD pa-
tients did not exhibit adverse events and induced clinic-
ally significant benefits regarding exercise capacity and
health-related quality of life. The clinical effects of WBV
were associated with decreased serum interleukin-8 levels
and increased levels of peroxisome-proliferator-activated
receptor-γ coactivator 1α (PGC1-α) and irisin, novel
markers of muscle activity. This data suggest WBV as a
potential training modality during an hospitalized acute ex-
acerbation of COPD.
Additional files
Additional file 1: Table S1. Description of Training Programme and
Physiotherapy Intervention. COPD patients were randomised to
participate either in the standard physiotherapy programme (Control
group) or in the standard programme with the addition of exercises on
the whole body vibration device (WBV group) Galileo™, Novotec Medical,
Pforzheim, Germany).
Additional file 2: Figure S1. Western Blot Analysis of PGC1- α. Displayed
are three representative blots of peroxisome-proliferator-activated receptor-γ
coactivator 1α (PGC1-α) transcript as measured by 10% SDS-Polyacrylamid-
gelelectrophoresis. CON: Control; WBV: Whole body vibration.
Additional file 3: Figure S2. SGRQ Subdomaines. Displayed are the
differences between admission and discharge. When comparing the deltas
between both groups (Whole body vibration, WBV: n = 20; Control, CON:
n = 19; Mann–Whitney-U test) we found a significant difference in favour of
WBV in the activity subgroup of the SGRQ. * p < 0.05.
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While white blood cell count (WBC, b) increased (most likely due to
systemic steroids), C-reactive protein (a), alpha-1-antitrypsin (c), and
interleukin-8 (d) decreased during the course of the study. When comparing
the deltas (discharge – admission) between both groups (Mann–Whitney-U
test) we found a significant difference in favour of whole body vibration
(WBV) regarding the reduction of IL-8. * p < 0.05; *** p < 0.001.
Additional file 5: Table S2. Additional Biological Data. Displayed are
markers of apoptosis, remodeling and angiogenesis at admission and
discharge. Data are displayed as mean ± standard deviation. Wilcoxon
matched-pairs signed-ranks test was used to compare differences between
day of admission and discharge in both groups and the Mann–Whitney-U-test
was used to compare the deltas of the groups (last column). Abbreviations are
explained in the text.
Additional file 6: Figure S4. 6-MWT, Corrections for Missing Values. To
account for missing values in the control group, we assumed the 6MWT on
the day of admission to be 3 m (lowest measured value). By this we corrected
for the underestimation that might have been introduced by missing
admission values in the control group. Still, whole body vibration (WBV)
increased the 6-minute walking test (n = 19) significantly more than control
(CON) physiotherapy (n = 20). * p < 0.05; ** p < 0.005; *** p < 0.001.
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